Macrogenics (MGNX) Cash & Current Investments (2012 - 2026)
Macrogenics (MGNX) reported Cash & Current Investments of $66.5 million for Q1 2026, down 54.31% year-over-year from $145.6 million in Q1 2025, and up 16.25% quarter-over-quarter from $57.2 million in Q4 2025.
Macrogenics (MGNX) Cash & Current Investments (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Cash & Current Investments data on file, last reported at $66.5 million in Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $66.5 million, down 54.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.5 million (down 54.31% YoY), and the FY2025 annual result was $57.2 million, down 68.71% from the prior year.
- Cash & Current Investments rose to $66.5 million in Q1 2026 per MGNX's latest filing, from $57.2 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $224.3 million in Q1 2023 and troughed at $21.5 million in Q2 2022.
- A 5-year average of $105.4 million and a median of $89.9 million in 2023 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments slumped 88.64% in 2022, then surged 406.58% in 2023.
- A 5-year view of Cash & Current Investments shows it stood at $108.9 million in 2022, then retreated by 7.28% to $101.0 million in 2023, then jumped by 81.11% to $182.8 million in 2024, then slumped by 68.71% to $57.2 million in 2025, then rose by 16.25% to $66.5 million in 2026.
- Business Quant data shows MGNX's Cash & Current Investments at $66.5 million in Q1 2026, $57.2 million in Q4 2025, and $80.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | 66.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.52 Mn |
| Dec 31, 2025 | 57.22 Mn |
| Sep 30, 2025 | 80.13 Mn |
| Jun 30, 2025 | 130.69 Mn |
| Mar 31, 2025 | 145.57 Mn |
| Dec 31, 2024 | 182.84 Mn |
| Sep 30, 2024 | 179.63 Mn |
| Jun 30, 2024 | 83.93 Mn |
| Mar 31, 2024 | 80.36 Mn |
| Dec 31, 2023 | 100.96 Mn |
| Sep 30, 2023 | 89.90 Mn |
| Jun 30, 2023 | 108.76 Mn |
| Mar 31, 2023 | 224.26 Mn |
| Dec 31, 2022 | 108.88 Mn |
| Sep 30, 2022 | 83.99 Mn |
| Jun 30, 2022 | 21.47 Mn |
| Mar 31, 2022 | 47.33 Mn |
| Dec 31, 2021 | 123.47 Mn |
| Sep 30, 2021 | 190.53 Mn |
| Jun 30, 2021 | 188.97 Mn |